Genmab A/S (NASDAQ:GMAB - Free Report) - Analysts at William Blair issued their FY2029 EPS estimates for Genmab A/S in a report released on Monday, March 10th. William Blair analyst M. Phipps forecasts that the company will post earnings of $4.38 per share for the year. William Blair has a "Outperform" rating on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%.
GMAB has been the subject of a number of other research reports. Sanford C. Bernstein raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Friday, December 20th. Truist Financial cut their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a research note on Thursday, February 13th. Finally, Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Genmab A/S presently has an average rating of "Moderate Buy" and a consensus target price of $41.33.
View Our Latest Analysis on Genmab A/S
Genmab A/S Trading Up 1.4 %
Shares of NASDAQ:GMAB traded up $0.29 during trading on Thursday, reaching $20.80. The company had a trading volume of 1,768,667 shares, compared to its average volume of 905,576. The company has a fifty day moving average of $21.24 and a two-hundred day moving average of $22.38. The stock has a market capitalization of $13.76 billion, a P/E ratio of 11.95, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. Genmab A/S has a 12 month low of $18.64 and a 12 month high of $31.02.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of GMAB. EverSource Wealth Advisors LLC boosted its stake in shares of Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after purchasing an additional 939 shares during the period. Lindbrook Capital LLC boosted its stake in shares of Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after purchasing an additional 950 shares during the period. GAMMA Investing LLC boosted its stake in shares of Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after purchasing an additional 1,051 shares during the period. Barclays PLC boosted its stake in shares of Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after purchasing an additional 2,285 shares during the period. Finally, Cromwell Holdings LLC boosted its stake in shares of Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock valued at $60,000 after purchasing an additional 2,496 shares during the period. Institutional investors own 7.07% of the company's stock.
About Genmab A/S
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Stories

Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.